Approval · Notice of Compliance 25503 · 2021
SANDOZ VALACYCLOVIR: Notice of Compliance 25503
Issued March 22, 2021
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 25503
- Date
- March 22, 2021
- Company
- Sandoz Canada Inc.Saint-Hubert, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Revisions to the product monograph
- Canadian reference product
- VALTREX (Glaxosmithkline Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SANDOZ VALACYCLOVIR | Not yet assigned | — |
Medicinal ingredients
- VALACYCLOVIR 500 MG per TAB